On March 4, 2021 PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, reported that it has priced an offering of $400.0 million aggregate principal amount of 2.550% Senior Notes due 2031 at an issue price of 99.965% of the principal amount and $400.0 million aggregate principal amount of 3.625% Senior Notes due 2051 at an issue price of 99.999% of the principal amount (Press release, PerkinElmer, MAR 4, 2021, View Source [SID1234576104]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The issuance of the notes is expected to close on March 8, 2021, subject to customary closing conditions. The notes will pay interest on a semi-annual basis.
PerkinElmer plans to use approximately $561 million of the net proceeds of the offering to repay amounts borrowed under its senior unsecured revolving credit facility to fund a portion of the purchase price for its acquisition of Oxford Immunotec Global PLC. PerkinElmer expects to use the remaining net proceeds of the offering to repay at maturity a portion of its outstanding €300.0 million aggregate principal amount of 0.600% senior notes due 2021.
The joint book-running managers for the offering are J.P. Morgan Securities LLC, BofA Securities, Inc., and Wells Fargo Securities, LLC.
The offering is being made pursuant to an effective registration statement on Form S-3 (including a prospectus) filed with the U.S. Securities and Exchange Commission ("SEC"). Prospective investors should read the prospectus forming a part of that registration statement and the prospectus supplement related to the offering and the other documents that PerkinElmer has filed with the SEC for more complete information about the company and this offering. These documents are available at no charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the prospectus supplement and the accompanying prospectus relating to the offering can be obtained by calling one of the joint book-running managers at the following: J.P. Morgan Securities LLC collect at 1-212-834-4533 or BofA Securities, Inc. toll-free at 1-800-294-1322.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the notes, nor shall there be any offer, solicitation or sale of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.